Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients.
Adolescent
Adult
Aged
Antineoplastic Agents
/ administration & dosage
Disease-Free Survival
Female
Humans
Leukemia, Myeloid, Acute
/ drug therapy
Male
Middle Aged
Mutation
Protein Kinase Inhibitors
/ administration & dosage
Quality of Life
Survival Rate
fms-Like Tyrosine Kinase 3
/ antagonists & inhibitors
AML
Chemotherapy
FLT3
Safety
Survival
TKI
Journal
Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
01
06
2020
revised:
14
12
2020
accepted:
22
12
2020
pubmed:
2
1
2021
medline:
2
4
2021
entrez:
1
1
2021
Statut:
ppublish
Résumé
Relapsed or refractory (R/R) acute myeloid leukemia (AML) has a poor prognosis, and new therapies are a major clinical need. When mutated, FLT3 drives neoplastic cell proliferation. New drugs (i.e., tyrosine kinase inhibitors, TKIs) showed effectiveness in FLT3-AML and promise to change disease history and outcome. We evaluated the benefit conferred by TKIs in terms of survival, burden of complications and surrogate endpoint of quality of life in a retrospective cohort of 49 FLT3 positive, R/R AML patients. Patients who received TKIs were compared to those treated with conventional chemotherapy. Treatment with TKIs conferred a better OS and wea associated with a lower burden and severity of adverse events. Importantly, patients who received TKIs showed reduced time of hospitalization. In conclusion, treatment with TKI in R/R FLT3-AML was related to a better survival, less and milder AEs, and shorter hospitalization.
Identifiants
pubmed: 33385697
pii: S0145-2126(20)30202-2
doi: 10.1016/j.leukres.2020.106497
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
FLT3 protein, human
EC 2.7.10.1
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
Types de publication
Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106497Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.